Buccal Drug Delivery Market Companies, and Competitive Landscape Market Players – Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; GlaxoSmithKline plc; Indivior Pharmaceuticals 2021 – 2030 BY Vision Research Reports

Latest Study on “Buccal Drug Delivery Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030”.

The global Buccal Drug Delivery market size is expected to be worth around US$ 8.9 billion by 2030, according to a new report by Vision Research Reports.

The global Buccal Drug Delivery market size was valued at US$ 6.8 billion in 2020 and is anticipated to grow at a CAGR of 10.2% during forecast period 2021 to 2030.

Get the Sample Pages of Report for More Understanding@ https://www.visionresearchreports.com/report/sample/38999

Growth Factors

Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Buccal drug delivery systems have gained significant growth potential due to constant research and development in this field. Compared to oral dosage form, buccal delivery is considered the most convenient and preferred choice, especially among geriatricpatients. This drug delivery route ensures elimination of first pass metabolism, allowing drugs thatarepH sensitive and easily degraded to be administered effectively.

Purchase this report (Price 3500 USD for single user license)@https://www.visionresearchreports.com/report/cart/38999

Report Coverage

Report Scope Details
Market Size US$ 8.9 billion by 2030
Growth Rate CAGR of 10.2% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Type, Application, End-user
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; GlaxoSmithKline plc; Indivior Pharmaceuticals; Generex Biotechnology; Catalent; ARx LLC; BioDelivery Sciences International, Inc.; Cynapsus Therapeutics Inc.; Endo Pharmaceuticals plc

By Type Analysis

The buccal tablets and lozenges segment captured the largest share of over 45.0% in 2020. Increased consumer acceptance, ease of formulation, cost-effectiveness, and wide availability of drug candidates for formulation are the factors responsible for the segment growth.

The sublingual films segment is expected to grow at the highest rate during the forecast period. Factors such as immediate availability of high concentration of drug at a target site and increased research to develop controlled release formulation are responsible for the high growth of the segment.

By End-user Analysis

The hospitals segment dominated the market with a share of over 40.0% in 2020. Increased admission in hospitals, especially of geriatric patients, the abundance of emergency care supplies, and product development and research by various community hospitals are the reasons behind this segment growth.

3 community hospitals in Japan conducted in vitro and in vivo studies to develop mucoadhesive microparticle-laden gels for oral mucositis. The result confirmed the high concentration of the drug at the target site and quicker treatment than traditional dosage forms are likely to improve the adoption.

By Application Analysis

The smoking cessation segment accounted for the largest share of over 31.0% in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction.

Increased research to treat sudden cardiac arrest outside hospitals and growing adoption of immediate treatment options have improved the acceptance of sublingual tablets, films, or even injections. This is responsible for the highest growth rate of the angina pectoris segment.

By Regional Analysis

North America dominated the market with a revenue share of over 31.0% in 2020. The presence of a large number of market players, improved research to identify suitable drug candidates, significant investment by large players to improve the development of newer formulations, and improved rate of diagnosis and treatment are the factors boosting the regional market growth.

Asia Pacific is expected to witness the highest growth during the forecast period. A rise in the geriatric population, the growth of the pharmaceutical industry, and an enormous rise in domestic players are likely to boost the regional market growth.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analyzed and prime business strategies and products that offer high revenue generation capacities were indentified. Key players of the global Buccal Drug Delivery market are included as given below:

Some of the prominent players in the Buccal Drug Delivery market include:

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Indivior Pharmaceuticals
  • Generex Biotechnology
  • Catalent
  • ARx LLC
  • BioDelivery Sciences International, Inc.
  • Cynapsus Therapeutics Inc.
  • Endo Pharmaceuticals plc

Market Segmentation

  • By Type
    • Sublingual Films
    • Buccal Tablets and Lozenges
    • Oral Sprays
  • By Application
    • Pain Management
    • Smoking Cessation
    • Angina Pectoris
    • Others
  • By End-user
    • Hospitals
    • Ambulatory Centers
    • Others

Regional Segmentation

  • Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia],
  • Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland],
  • North America [United States, Canada, Mexico],
  • South America [Brazil, Argentina, Columbia, Chile, Peru].
  • Middle East & Africa [GCC, North Africa, South Africa],

Why should you invest in this report?

If you are aiming to enter the global Buccal Drug Delivery market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for Buccal Drug Delivery are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Table Of Content

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Buccal Drug Delivery Market, By Type

7.1.  Buccal Drug Delivery Market, by Type, 2021-2030

7.1.1.    Sublingual Films

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Buccal Tablets and Lozenges

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Oral Sprays

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Buccal Drug Delivery Market, By Application

8.1.  Buccal Drug Delivery Market, by Application, 2021-2030

8.1.1.    Pain Management

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Smoking Cessation

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Angina Pectoris

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Others

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Buccal Drug Delivery Market, By End User

9.1.  Buccal Drug Delivery Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Ambulatory Centers

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Others

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Buccal Drug Delivery Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Type (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Type (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Type (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Type (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Type (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Type (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Type (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Teva Pharmaceutical Industries Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Pfizer Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              GlaxoSmithKline plc.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Indivior Pharmaceuticals

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Generex Biotechnology

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Catalent

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              ARx LLC

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              BioDelivery Sciences International, Inc.

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Cynapsus Therapeutics Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Endo Pharmaceuticals plc

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

 Buy This Premium Research Report (Single User USD 3500), Click Here@ https://www.visionresearchreports.com/report/cart/38999

About Us

Vision Research Reports is unquestionably an expert in providing research reports on a diverse number of subjects including Alternative and Green Energy, Chemical, Energy, Glass, Machinery, Manufacturing, and Pharmaceuticals and Materials. We cater to distinguished MNCs, private equity firms, SMEs and Chinese companies pertaining to their market research data requirements.

We offer generic and amalgamated studies as well as customized studies to our clients based on their specific requirements. Our modus operandi constitutes of detailed and meticulous market surveys, company profiling, competitive landscaping and primary interviews. Our prudent insights have been vital in the inception of many investment programs, new project development programs, startups and technology breakthroughs.

Contact Us:

Call: +1 9197 992 333

Vision Research Report

Any Assistance, Email – sales@visionresearchreports.com

James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.